Following its acquisition by Supernus Pharmaceuticals, Sage Therapeutics has let go of all of its remaining workforce, which ...

Novartis announced top-line results from the phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx ...

Novartis NVS announced that a late-stage study of its interleukin-17A inhibitor, Cosentyx (secukinumab), has failed to meet ...

Researchers have found in a new research that among adults with diabetic kidney disease (DKD), adjunctive hemodialysis ...

EAST HANOVER, NJ, USA I July 3, 2025 I Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in ...